What’s new in aHUS research? Quite a bit, if you consider that over four dozen publications have just been added to our aHUS-specific ‘Virtual Library’. There’s a reason we’re so…
This is a plain language summary of the final article to be published about Stopping Eculizumab Treatment Safely Clinical Trial. The aim of the Stopping Eculizumab Treatment Safely atypical haemolytic…
From start to finish it’s been a busy year in the global ‘aHUS space’ yet before we say hello to 2026 issued our December 2025 edition of The aHUS Global…
Keeping track of medical advancements in the rare disease space is challenging, but for those interested in atypical HUS the aHUS Alliance Global Action team 'rounds up' new publications every…
What is it like from an aHUS patients' perspective to decide to withdraw from complement inhibitor treatment? Much is published about stopping complement inhibitor treatment but not from a patients…
It is said that thrombomodulin, or TM (AKA THBD) ,or CD141, plays only an indirect part in TMA (thrombotic microangiopathy) . TM is something which is ubiquitously spread on the…
A PDA or patient decision aid is becoming an important part of the increasing shared decision making by patients and doctors. How do patients prepare themselves for a discussion on…
A few days ago an article appeared in The Lancet which claims to be the largest real world analysis of complement inhibitor treatment of aHUS patients. It is a retrospective…